Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EYEN Eyenovia	$10.88 +37.9%	$2.72	$0.85 ▼ $124.80	$31.36M	1	1.22 million shs	6.02 million shs
FBLG FibroBiologics	$0.62 -13.2%	$0.90	$0.62 ▼ $5.62	$23.65M	-0.8	298,756 shs	3.35 million shs
PMCB Nuvilex	$1.03 -1.9%	$1.09	$1.00 ▼ $2.42	$7.07M	-0.44	19,361 shs	5,335 shs
SXTC China SXT Pharmaceuticals	$1.72 -1.1%	$1.77	$0.95 ▼ $11.92	$27.22M	1.11	1.20 million shs	20,632 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EYEN Eyenovia	+37.90%	+158.43%	+551.50%	+862.83%	-78.41%
FBLG FibroBiologics	-13.19%	-11.14%	-20.03%	-34.94%	-86.23%
PMCB Nuvilex	-1.90%	-2.83%	-3.74%	-21.97%	-48.76%
SXTC China SXT Pharmaceuticals	-1.15%	-6.52%	+13.16%	-38.13%	-79.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EYEN Eyenovia	1.0065 of 5 stars	1.0	5.0	3.2	0.0	0.6
FBLG FibroBiologics	2.6805 of 5 stars	3.6	2.0	2.2	2.5	0.6
PMCB Nuvilex	1.0794 of 5 stars	0.0	3.0	3.8	0.8	0.6
SXTC China SXT Pharmaceuticals	0.4584 of 5 stars	0.0	3.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EYEN Eyenovia	2.00	Hold	$2.00	-81.62% Downside
FBLG FibroBiologics	3.20	Buy	$13.00	2,003.22% Upside
PMCB Nuvilex	0.00	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PMCB, SXTC, FBLG, and EYEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/15/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/9/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/1/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/1/2025	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EYEN Eyenovia	$60K	522.24	N/A	N/A	($695.52) per share	-0.02
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$0.08 per share	N/A
PMCB Nuvilex	N/A	N/A	N/A	N/A	$3.27 per share	N/A
SXTC China SXT Pharmaceuticals	$1.93M	14.11	N/A	N/A	$243.66 per share	0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EYEN Eyenovia	-$49.82M	-$58.40	N/A	N/A	N/A	-62,238.41%	-1,108.24%	-316.90%	8/11/2025 (Estimated)
FBLG FibroBiologics	-$11.16M	-$0.21	N/A	N/A	N/A	N/A	-1,022.04%	-117.56%	8/6/2025 (Estimated)
PMCB Nuvilex	$330K	$0.74	1.39	∞	N/A	N/A	0.51%	0.35%	8/11/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest PMCB, SXTC, FBLG, and EYEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/19/2025	Q1 2025	EYEN Eyenovia	-$7.20	-$1.59	+$5.61	-$1.59	$1.60 million	$1.60 million
5/13/2025	Q1 2025	FBLG FibroBiologics	-$0.10	-$0.14	-$0.04	-$0.14	N/A	N/A
3/31/2025	Q4 2024	FBLG FibroBiologics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EYEN Eyenovia	N/A	N/A	N/A	N/A	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
PMCB Nuvilex	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EYEN Eyenovia	0.58	0.34	0.34
FBLG FibroBiologics	N/A	1.14	1.14
PMCB Nuvilex	N/A	14.21	14.21
SXTC China SXT Pharmaceuticals	0.01	1.40	1.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EYEN Eyenovia	25.84%
FBLG FibroBiologics	N/A
PMCB Nuvilex	34.24%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
EYEN Eyenovia	7.10%
FBLG FibroBiologics	20.00%
PMCB Nuvilex	10.20%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EYEN Eyenovia	40	2.88 million	2.68 million	Optionable
FBLG FibroBiologics	10	38.26 million	30.61 million	N/A
PMCB Nuvilex	4	6.86 million	6.16 million	Optionable
SXTC China SXT Pharmaceuticals	90	15.83 million	15.20 million	Not Optionable

PMCB, SXTC, FBLG, and EYEN Headlines

Recent News About These Companies

China SXT Pharmaceuticals Inc News (SXTC) - Investing.com

June 25 at 2:26 AM | investing.com

China SXT Pharmaceuticals Issues 90 Million Shares Following Warrant Exercise

June 16, 2025 | tipranks.com

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.comM

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.comB

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

china sxt pharmaceuticals - SXTC

October 3, 2024 | foxbusiness.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock, Short Interest Report

October 1, 2024 | benzinga.com

Can China SXT Pharmaceuticals Inc (SXTC) Stock rise from its doldrums?

July 24, 2024 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock creates opportunities due to its volume and complexity

May 21, 2024 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB, SXTC, FBLG, and EYEN Company Descriptions

Eyenovia NASDAQ:EYEN

$10.88 +2.99 (+37.90%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$10.98 +0.09 (+0.87%)

As of 06/27/2025 08:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

FibroBiologics NASDAQ:FBLG

$0.62 -0.09 (-13.19%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.64 +0.03 (+4.35%)

As of 06/27/2025 07:54 PM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Nuvilex NASDAQ:PMCB

$1.04 -0.01 (-1.33%)

As of 06/27/2025 04:00 PM Eastern

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.72 -0.02 (-1.15%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.70 -0.02 (-1.16%)

As of 06/27/2025 07:49 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time